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Comparison of basic fibroblast growth factor levels in clone A human
colon cancer cells in vitro with levels in xenografted tumours
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S-ry We measured levels of basic fibroblast growth factor (FGF-2) in human colon carnr cells (clone
A) in vitro and in xenografted solid tumours usin a al enzyme-linked immunoassay. In Vitro, kvels
in unfed plateau phase or exponentially growing cells were low, averaging respectively about 2 and 8 pg 10-6
cels. However, when solid tumours (average volumes 787 mm3) wre cut into halves and either enzymatically
disaggregted to obtain a ceilular fraction or extracted in toto, kvels were much higher. In the chlluar fraction,
vahles averaged 110 pg 10' cells, while in whole tumour extracts, average values were 24 pg mg-' tumour
tissue. These results indicate that growth factor kvels in sobd neoplasms may differ markedly from those
predicted from in vitro measurements. We hypothsise that the apparent increase in FGF-2 kvels in vivo results
primarily from the presence of a significant fraction of host cells m particular. macrophages, which may
contain high kvels of FGF-2) within xenogafted done A neoplasm.
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Angiogenic peptides such as basic fibroblast growth factor
(FGF-2) appear to have substantial roles in the regulation of
tumour growth (Soutter et al., 1993; Nguyen et al., 1994) and
therefore may be considered targets for anti-angiogenesis
cancer treatments, possibly in conjunction with chemo- or
radiotherapy (Jenks, 1994). Such combined therapies, how-
ever, may present subtle problems. For example, we have
shown that treatment of xenogafted human tumours with
exogenous FGF-2 increases growth rates and decreases
hypoxia levels (Leith et al., 1992; Leith and Mitchelson,
1993). Conversely, administration of suramin, a growth fac-
tor receptor-blocking agent, slows tumour growth while in-
creasing steady-state levels of hypoxia (Leith et al., 1992).
Because hypoxic cells are radiation isaant, strategies that
rely upon blocking neovascularisation could produce an
unfavourable radiotherapeutic situation. With this caveat in
mind, we investigated some aspects of tumour biology related
to the feasbility of a radiotherapeutic/anti-angiogenesis app-
roach.
We have previously determined steady-state levels of intra-
tumour hypoxia in a large number of xenografted solid
human colon cancers in nude mice, and demonstrated that at
similar volumes percentages of hypoxia varied from ess than
1% to over 80% (Leith et al., 1991a). These widely divergent
results led to the hypothesis that variabilaity in hypoxia
expression might be inversely related to intraneoplastic levels
of angiogenic factors such as FGF-2. According to this logic,
cells that produce high levels of FGF-2 would generate well-
vascularised solid tumours. Then, as a consequence of this
putative well-vascularized situation, such neoplasms should
in turn express low steady-state levels of hypoxia. Therefore,
we determined levels of FGF-2 both in vitro and in vivo for
the human colon tumour cell line, clone A, chosen because
hypoxia levels in these neoplasms are low (-,3%) (Leith et
al., 1991a). Based on our hypothesis, we a priori predicted
that high cellular levels of FGF-2 would be present. Unex-
pectedly, however, we found that FGF-2 levels in vitro on a
per cell basis were not only very low, but were also several
orders of magnitude less than in vivo levels.
Materils ad
Ceu line
The clone A cell lne was established in 1978, at the Roger
WViliams Cancer Center, Providence, RI, USA, from a
biopsy specmen from a male patient with a poorly to
moderately differentiated primary colonic adenocarcinoma.
The primary tumour was found to be heterogeneous, and
two cell lines (clones A and D) which differ significantly in
morphology and chromosomal number were established.
Details on subpopulation isolation have been published
(Calabresi et at., 1979; Dexter et al., 1981). For these
experiments, stock cells stored in liquid nitrogen were grown
in RPMI-1640 medium containing 10% fetal bovine serum
(FBS), 1% sodium biarbonate, 1% anti-PPLO reagent, 1%
4-(2-hydroxyethyl)-lppen th honc acid buffer
and 0.5% gentam (all reagents from Grand Island
Biological, Grand Island, NY, USA).
Mice andproduction ofxenograft twnours
Young adult male nude mice were obtained from the Charles-
River Breeding Laboratories, North Wilmington, MA, USA.
Mice were housed, ten per large cage, with dust covers, in a
dedicated room in a laminar flow hood (Trhoren Industries,
King of Prussia, PA, USA). Mice were quarantined for 1
week and were ear tagged for identification. To produce
tumours (one per animal), clone A cells were trypsnised
(0.05% trypsin, 0.54 mM EDTA) from exponentially growing
cultures, and resuspended as single cells in Hanks' basic salt
solution (HBSS) at a concentration of 5 x I0' cells ml-'. A
0.2ml volume of the cell suspension was injected into the
right flankr region of each mouse.
Determination ofin vitro andin vivo levels ofFGF-2
In vitro, clone A cells were enzymatically removed from
either exponentially growing, unfed or fed plateau cultures
(cell densities rspectively 3 x 10, 5 x 0I and 2.5 x 106
cells cm-), using either trypsin (0.05% trypsin, 0.54 mM
EDTA) or pronase (0.25% nuckase-free neutral protease
(Calbiochem, San Diego, CA, USA). Cultures were initiated
at a density of IO' cells cm-2, and were respectively assayed
for FGF-2 levels at 3, 8 and 11 days post-seeding. For the
fed plateau cultures, the medium (50ml 175 cm-2 flask) was
changed daily. The two different enzymes were compared to
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February 1995see if the specific protease used affected FGF-2 levels. Addi-
tionally, exponentially growing cells were removed from
flasks by mechanical scraping as a control to determine if
enzymatic removal in general affected FGF-2 levels. Cells
were centrifuged, resuspended and washed twice in ice-cold
Dulbecco's phosphate-buffered saline (DPBS). Cell lysates
were prepared by resuspension of cells (final concentration
2 -5 x I07 cells ml-l) in an extraction buffer (4'C) containing
10 mM Tris-HCI (pH7.0). 2M sodium chloride, 0.02% (3-[(3-
cholamidopropyl)-dimethylammoniol- I-propanesulphonate)
(CHAPS, Sigma. St. Louis. MO. USA) and protease inhibi-
tors [2 jg ml-1 bestatin. pepstatin, and elastatinal, 400 jiM
leupeptin (Sigma) and 2 jLg ml1 I phenylmethylsulphonyl
fluoride (Boehringer Mannheim Biochemicals, Indianapolis.
IN, USA)]. The lysate was sonicated (4-15 s bursts on ice.
70-80% power, Heat Systems sonicator. model 225-R.
Farmingdale, NY, USA). and centrifuged (4°C, 26 900g, 2 h,
Beckman J2-21 centrifuge, Beckman Instruments, Palo Alto.
CA, USA to produce the cell extract supernatant for assay.
In vivo, each tumour was sterilely removed and cut into
approximately equal halves. Both halves were then weighed
and minced using opposed scalpel blades into fragments of
less than 1 mm3. One of the halves was disaggregated into
single cells in a stirred (40 min, 37C) enzyme cocktail consis-
ting of 0.2% RNAse-free DNAse (Sigma), 0.25% collagenase
(Boehringer Mannheim), 0.25% nuclease-free neutral pro-
tease (Calbiochem) in RPMI-1640. This disaggregate was
then sieved through an 80 jim2 rectangular steel mesh, cent-
rifuged (1000 r.p.m., 10mn, 4'C), resuspended and counted
by haemocytometer. The other tumour half was not
enzymatically disaggregated. Instead, the mince fragments
were extracted in toto in complete lysis buffer. Therefore.
assays of the two halves of each neoplasm represent directly
comparable levels of FGF-2 in the tumour parenchyma (P
compartment, enzyme disaggregate) and in the parenchymal
plus non-parenchymal compartments (P + NP, in toto extrac-
tion).
FGF-levels were determined in replicate from each in vitro
or in vivo sample supernatant using an enzyme-linked
immunoassay (ELISA) kit (R&D Systems, Minneapolis, MN,
USA). Means and s.e.m.s were determined from logs of
individual determinations. Protein levels in samples were
determined using the Bradford assay (BioRad. Richmond
CA, USA).
Determination ofKD and B,,, for FGF-basic high-affinity
binding sites
Our assay was adapted from previously described protocols
(Moscatelli, 1986; Murthy et al., 1989). Cells from stock
cultures were washed once with DPBS, trypsinised. counted
by haemocytometer and seeded in 24 well culture plates (Cos-
tar, Cambridge. MA. USA) at a density of 6 x 104 cells per
well. Forty-eight hours after seeding and 2 h before the
experiment, cells were washed twice with 0.5 ml of ice-cold
DPBS and incubated at 37°C in 0.5 ml of Ex-Cell (JR Bios-
ciences, Lenexa, KS, USA) with 0.1% bovine serum albumin
(BSA) (Calbiochem) and 25 mM Hepes, pH 7.5. Cells were
washed twice with 0.5 ml of ice-cold DPBS, and an appropri-
ate concentration of 'I51-labelled recombinant human FGF-2
(specific activity 124 jCijg-) (New England Nuclear, Bos-
ton, MA, USA) in Ex-Cell (0.1% BSA, 25 mM Hepes, pH
7.5) was added to each well (each concentration was assayed
in duplicate) in a final volume of 400 jil. After addition of
labelled FGF-2, cells were incubated for 2 h at 4°C on an
orbital shaker to permit saturation of binding sites. Follow-
ing incubation, cells were washed twice with 0.5 ml of ice-
cold DPBS and cell-bound '251I-labelled FGF-2 was analysed
by solubilising cells with 1 ml per well 0.5% Triton X-100 in
0.1 M sodium phosphate, pH 8.1 (20 mmn, room temperature)
on an orbital shaker. Cell-bound'"I-labelled FGF-2 (c.p.m.)
was determined using a Beckman Gamma 4000 gamma-
counter (Beckman Instruments), which has a counting
efficiency for "2I of 0.77 c.p.m./d.p.m. Non-specific binding
was determined using a 250-300 molar excess of recom-
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binant human FGF-2 (R&D Systems) in addition to appro-
priate concentrations of "51-labelled FGF-2. KD and B,
were determined using a non-linear regression fit of total
binding data from three independent experiments to the
model X(Bm) KD + X (NSB) where X is the concentration of
radiolabelled ligand and NSB is the non-specific binding. In
each experiment representative wells were trypsinised and
counted by haemocytometer to allow calculation of the
number of binding sites per cell.
Cellproliferation studies
Mitogenic responses to exogenously administered FGF-2
were measured using an MTT colorimetric assay. For the
MTT assay, cells were seeded into 24 well plates (Costar) at a
density of 1.3 x 105 cells per well in 2 ml of complete RPMI-
1640 medium containing 10% FBS and incubated at 37C for
48 h. Cells were then washed once with DPBS preheated to
37°C and incubated in 1 ml of Ex-Cell 300, chemically
defined medium at 37'C for 24 h. Following the incubation in
defined medium, varying concentrations of FGF-2 or vas-
cular endothelial growth factor (VEGF) were added to each
well in a volume of 100jl of sterile deionised water with
0.02% CHAPS (Sigma) detergent. After the addition of
FGF-2. cells (with appropriate negative controls) were
incubated at 37C for an additional 48 h. MTT reagent was
then added to each well at a final concentration of
0.5 mg ml-' and cells were incubated at 37°C for 4 h. Next.
cells were solubilised overnight using 1 ml of 10% SDS in
0.01 M hydrochlonrc acid. Aliquots from each well were
transferred to a 96 well ELISA plate (Costar) and read at
590 nm with a microplate reader (Bio Tek Instruments,
Woonski, VT, USA). Samples were assayed in triplicate.
Ribonuclease protection assay
Poly(A)+ RNA was prepared using the Fast Track mRNA
isolation system (Invitrogen. San Diego. CA, USA).
Polymerase chain reaction (PCR}-specific primers were
designed from sequences obtained from GenBank and were
subjected to presynthesis analysis for dimerisation and
specificity with the aid of Amplify vl.2 (Dr Bill Engels.
University ofWisconsin). Primers were synthesised by Oligos.
Etc. (Wilsonville. OR, USA). DNA templates incorporating
promoters for phage polymerases are necessary for produc-
tion of an antisense-labelled probe for use in ribonuclease
protection assay. Synthesis of the required template by PCR
was accomplished using a reverse primer that incorporated a
T7 phage promoter sequence upstream of the primer binding
region. FGF-2 template DNA was made from a plasmid.
pHFL1-7, containing an 800 bp fragment of the cDNA for
FGF-2 (courtesy Dr Judith Abraham, Scios Nova, Mountain
View, CA, USA). PCR was performed directly on the plas-
mid. Sequences of FGF-2 primers used in template synthesis
were as follows:
5'-CAAGCAGAAGAGAGAGGA-3'(forward)
5'-AATCTCTAATACGACTCACTATAGGGAGGG
CTCTTAGCACACATTGG-3' (reverse)
In vitro transcription was performed using MAXIscript
(Ambion. Austin, TX. USA). Template DNA was incubated
at ambient temperature for 60min with 0.5mm ATP. CTP
and GTP. 10 mM DTT. 0.5 mCi ota1-32P]UTP at 800 Ci
mmol-1, 12.5 U of human placental ribonuclease inhibitor
and 10 U of T7 RNA polymerase. A lower specific activity
human P-actin control template was synthesised with 0.1 mCi
of [M-32P]UTP and 0.1 mm UTP. Transcription was ter-
minated by the addition of 2 U of DNAse I followed by a
15 min incubation at 37C. Radiolabelled probe was purified
by electrophoresis on a 5% acrylamide, 8 M urea polyac-
rylamide gel. The probe hu-FGF-2 was synthesised at app-
roximately 1.3 x 109 c.p.m. mg-', and the probe for human
A-actin was synthesised at approximately 1.6 x 103
c.p.m. mg'.
Numbers oftranscripts for FGF-2 in vitro and in vivo wereFg-2 in ma cE_wco E
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detrmined using RPA II according to the indicated protocol
(Ambion). Total RNA or poly(A)+ and radiolabelled probe
were co-precipitated in 0.5 M ammonium oxyacetate, 2.5
volumes of ethanol and hybridised for 18 h at 42-45C.
Samples were then digested at 37C with a mixture of 0.5 U
of RNAse A and 2 U of RNAse TI. Following subsequent
RNAse inactivation and precipitation, protected fragments
were visualised by electrophoresis on a 5% acrylamide, 8 M
urea polyacrylasmide gel. Gels were exposed for 16-20h.
Following exposure, bands were removed from the gel and
solubilised in 5% Soluene (Packard Instruments, Meriden,
CT, USA), 95% scintillation cocktail. The radioactivity of
each excised band was quantified with a scintillation counter
(Packard Instruments).
Rests
Table I summarises findings for FGF-2 levels for cells from
either exponentially growing or unfed plateau conditions in
vitro, together with in vivo values for clone A cells obtained
from either enzymatialy diegated xenografted solid
tumours or the entire (non-disaggregated) tumour. Addi-
tionally, FGF-2 levels in cells in vitro after removal from
flasks by mechanical scraping were assayed in order to deter-
mine if the enzymatic treatments affected FGF-2 levels. For
the in vivo data, care was taken to examine FGF-2 levels in
neoplams of the same average volume (,750mm3) as that
at which determinations of hypoxia have been previously
made (Leith et al., 1991a). Average tumour volumes (n = 9)
were 787 mm3(s.e.m. 700-887mm3). Geometric mean weights
(mg) and s.e.m.s for the halves of the tumours used respec-
tively in the extraction only and the enzymatic disaggton
plus extraction assays were 318.1 (270.0-374.7) and 306.0
(248.6-376.6). Geometric mean colony-forming efficiencies
and s.e.m.s were respectively 17.6% (15.0-20.8) in vivo and
57.0% (49.4-65.8) in vitro (Leith et al., 1991b). Cell yields
from enzymatcally disaggregted clone A neoplasms (n = 9)
were 5.58 ± 1.86 x 10' cellsmg-' (s.e.m.) and median cell
volumes were 17001m3.
A number of points may be made from the results shown
in Tables I and H. First, on a per cell basis, both fed and
unfed plateau phase cells show decreased levels of FGF-2
(1.4 and 2.1 pg 10-' cells respectively) as compared with
exponentially growing cells (7.7 pg 10-6 cells), indicating that
growth status and/or cell cycle position affects FGF-2 levels.
Second, exposure of exponentially growing cells (about
5 x 10' cellscm-) to a hypoxic environment for 16 h yielded
FGF-2 results similar in magnitude to klvels in unfed plateau
cells. Measurements of FGF-2 in the medium ovrlying
exponentially growing or plateau phase cells consistently
showed no measurable levels of FGF-2.
Third, the FGF-2 levels m cells detached from flasks by
two different enzymatic treatments (trypsin/EDTA or pro-
nase) were not different from results from cells removed from
flasks by mhanical scraping, indicating that the enzymatic
treatments did not affect subsequent determinations of int-
racellular FGF-2 levels.
Fourth, FGF-2 klvels in clone A cells established as short-
term (two passags) tissue cultures directly from tumour
disaggregates were similar to levels in established cultures. It
is therefore unlikely that the in vivo results reflect selction
for cells that express high FGF-2 levels.
The binding site studies showed that clone A cells possess
FGF-2 high-affinity binding sites. The mean KD was 48.8 pM
with an asymptotic standard error of 23.3 pM. Determina-
tions of the mitogenic response ofclone A cells to exogenous
FGF-2 indicated that the FGF-2 concentration needed to
produce a half-maximal siulatory response (ED_%) was
4.8 pM.
Excision of the labeled FGF-2 bands from the
ribonuckase protection assays with subsequent scintillation
counting showed that the c.p.m. values normahsed to a
human P-actin internal standard in each experiment were
respectively 0.91 (s.e.m. 0.12) and 1.02 (s.e.m. 0.08) for the in
vitro and in vivo conditions. That is, there was no difference
in mRNA levels for human FGF-2 in clone A cells taken
from exponentially growing cultur and whole xenografted
clone A tumours. Because the ribonuckase protection assay
degrades probe-target duplexes containing even a single base
pair mismatch, the assay was specific for human FGF-2
transcripts.
The most significnt finding of these experiments is that the
levels of FGF-2 within clone A cells in vitro are low while
levels in xenografted clone A neoplasms are much higher
than would be predicted based simply on the results of in
vitro assays. Based on in vitro data alone, one would instead
predict that clone A neoplasms should express high rather
than low levels of hypoxia. This prediction however also
fails, as the hypoxic percentage in clone A neoplasms at this
volune is about 3%, a value which is quite low as compared
with other xenogafted human colon tumours at similar
volumes which express higher hypoxia levels and con-
comitantly higher in vitro levels of FGF-2 (Leith et al.,
1991a). The resolution to this paradox is, however, indicated
Table I Levels ofFGF-2 in human colon canor cells (clone A) in vitro and in vivo
Nvnber of FGF-2 FGF-2
Growth state experimem (pg 10- cels) (pgmg-' cells)
In vitro
Esablished cultures
Exponential 6 6.6(5.3-8-2)b
(trypsin/EDTA)a
Exponential 4 8.0(5.8-11.0) -
(pronase)r
Mechanical
sraping 2 7.3(7.0-7.7)
Unfed plateau 3 2.1(1.9-2.3) -
Fed plateau 3 1.4(0.6-2.9) -
Nitrogen gassedc 3 2.8(2.5-3.3) -
Short-term cultures 2 7.0(4.4-9.6) -
In vivo
Tumour disaggregate 9 110.2(75.9-159.9) -
Tumour extract 9 - 24.2(18.2-33.6)
aJI vitro experiments done on cells detached from fasks by different enzymatic treatments
(typsin/EDTA or pronase). bVahues are means and sem..s. 9termination ofFGF-2 levels in
cls after exposure to a 95% nitrogen/5% arbon dioxide gas enviroent for 16h. *Values
determined indoneAculresafter e-esablshmentofcells invitrodirectlyfromezymatically
disaWegated solid tumours.FGF-2 in hwnan colon tmxw cuk
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Table H Statistical comparisons oflevels of FGF-2 in human colon cancer cells (clone A) in vitro
Exponential Exponential Mechanical Unfed Fed Nitrogen Short-term
Growth States (trypsin/EDTA) (pronae) scraping plateau plateau gassed cultures
Exponential - t= -0.50 t= -0.32 t= 4.20 t=2.49 t=2.94 t = 0.028
(trypsin{EDTA) - P = NS' P=NS P=0.01 P=0.05 P= 0.05 P=NS
Exponential - - t = 0.18 t=3.44 t=2.63 t=2.60 t = 0.38
(pronase) - - P=NS P=0.01 P=0.05 P= 0.05 P=NS
Mechanical - - - t= 10.68 t=2.20 t=5.11 t = 0.30
scraping - - - P= 0.01 P=NS P= 0.01 P=NS
Unfed plateau - - - - t= 0.74 t=-1.79 t =-3.61
- - - - P=NS P=NS P=0.01
Fed plateau -t- - 1- - t=-.22 t=-1.82
- - - - - P=NS P=NS
Nitrogen gassed - - - - - - t=-2.42
- - - - - - P= 0.05
'P-valuesforthevariouscomparisons arereported aseithernon-significant(NS) or assignificant ateitherthe0.05 or0.01 levels
of probability (Goldstein, 1964).
by the result that average FGF-2 values in cells from
enzymatically disaggregated tumours were 110 pg O-6 cells
- aproximately a 50-fold increase over levels in unfed
plateau cells.
There are therefore two interrelated issues which need to
be addressed. The first issue involves consideration of the
processes that might lead to such results, and the second
involves the potential significance of these results vis-i-vis
autocrine and paracrine effects of FGF-2.
The most straightforward explanation of why high levels
of FGF-2 are found in vivo is increased production of FGF-2
in clone A cells on a per cell basis, suggesting that growth in
vivo up-regulates FGF-2 levels. However, while Higgins et al.
(1991) have shown that hypoxia, for example, appears to
increase significantly mRNA levels for FGF-2 in Y-79
retinoblastoma cells, no effects of hypoxia on FGF-2 mRNA
levels have been seen in C6 glioblastoma cells (Shweiki et al.,
1992). Several results from our experiments suggest that
clone A cells did not increase their steady-state levels of
FGF-2 in vivo.
First, no effects of long-duration hypoxic exposure (16 h)
on FGF-2 levels in clone A cells were seen (Table I).
Second, levels of FGF-2 in unfed plateau phase cultures
were low as compared with exponentially growing cultures.
T1his might indicate a cell cycle block induced by the hypoxia
in GI (Rice et al., 1985). While, to our knowledge, there have
been no studies on levels of FGF-2 per cell as an explicit
function of cell cycle phase, Bost and Hjelmeland (1993)
showed that levels of a major 7.0 kb FGF-2 transcript in
retinal epithelium decreased by a factor of about 15 in
exponential vs confluent cultures. Additionally, not only does
the transcript level decrease, the half-life of the transcript
decreases from about 24 h to about 17 h. Such changes are
probably allied to the decreased FGF-2 protein levels we find
in fed and unfed plateau phase clone A cells. With regard to
these two points, cell cycle distributions (G1, S, G2+M) in
exponentially growing and unfed plateau phase cultures of
clone A cells are respectively about 53, 24 and 22%, and 78,
14 and 8% (Bliven et al., 1987). The simplest initial assump-
tion would be that the concentration of FGF-2 per cell (i.e.
fgpm-3) does not change throughout the cell cycle, and that
measured levels change only as the change in relative cell
volume as cells progress from G1 to G2 + M (Bliven et al.,
1987). However, normalisation of cellular FGF-2 contents
using such a volumetric approach based on the distribution
of cells through the cell cycle does not account for the
approximately 70% decrease in average cellular FGF-2 levels
(Table I). Indeed, FGF-2 levels would only decrease by
about 15% using this approach. Therefore, it appears that
decreased growth rates in the plateau phase are associated
with an absolute decrease in cellular FGF-2 levels. In this
regard, it is important to note that our determinations of
FGF-2 levels in fed and unfed plateau phase cultures were
done under conditions (e.g. use of 175 cm2 flasks containing
respecively about 2.5 x 106 and 5 x I0 cellscm2 with a
medium depth of 0.286 cm) that might be associated with
respiration-induced hypoxia (Koch, 1979). Although res-
piratory rates of plateau phase cells are often less than that
in exponential growth, we do not know respiratory rates
(mol s-' per cell) of either exponential or plateau phase clone
A cells. This caveat could also apply to the work of Bost and
Hjelneland (1993) cited above.
Third, assay of FGF-2 levels in clone A cultures in vivo
shortly after establishment from disaggregated neoplasms
were not different from levels seen in established cultures
(Table I). Moreover, FGF-2 levels in clone A cells (e.g.
-2 pg 10-6 cells in in vitro unfed plateau cultures) are among
the lowest in 14 different human colon cancer cell lines
studied in vitro to date (J Leith, unpublished data).
Fourth, because the ribonuclease protection assay degrades
probe-target duplexes containing even a single base pair mis-
match, the assay was specific for human FGF-2 transcripts
and showed no differences in FGF-2 mRNA levels as nor-
malised to human P-actin mRNA levels between preparations
from clone A cells in vitro and whole tumours. This strongly
implies that the increased levels of FGF-2 seen in protein
assays are derived from the host. We therefore do not view
the increased levels of FGF-2 seen in vivo as resulting from
biochemical/molecular changes in clone A cells per se.
Another possibility as to why FGF-2 levels are unpredic-
tably high in vivo is storage of FGF-2 by heparan sulphate
proteoglycans (HSPGs) in either cell-attached or extracellular
compartments (Vlodavsky et al., 1991). Our measurements of
FGF-2 levels per mg of tumour do not provide insight into
the microscopic distribution of FGF-2, and we do not know
levels of FGF-2-binding HSPGs in clone A neoplasms. How-
ever, significant levels of HSPGs have been shown in other
tumour systems (Esko et al., 1988), and there is a priori no
reason to assume otherwise for clone A tumours. FGF-2
released from cells could be bound to HSPGs for a sufficient
amount of time to account for the increased levels seen in
vivo. Indeed, FGF-2 binding to ECM HSPGs has been des-
cribed as 'highly stable' (Vlodavsky et al., 1991), although it
will be a function of factors such as specific tumour
heparanase levels, which vary significantly (Nakajima et al.,
1990; Vlodavsky et al., 1991).
Increased FGF-2 levels seen in vivo may result from host
cells. Host cells in disaggregated clone A adenocarcinomas at
this volume, measured from Giemsa-stained cytospin slides,
constitute 40% of the total cells counted by haemocytometer
(;27% macrophages, 10% small lymphocyte-type cells and
2-3% neutrophils; Leith and Michelson, 1994). The
significant host cell fraction partly accounts for the fact that
the average tumour cell colony-forming efficiencies (CFEs)
from disaggregated neoplasms are less than in vitro CFEs.
Another factor that contributes to the decreased CFE is that
clone A cells in early GI have a CFE that is about 50% of
that of clone A cells at other positions in the cell cycle
(Bliven et al., 1987).
Cell yields from enzymatically disaggregated clone A neop-
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lasms were 5.58 x 104 cells mg-' and median cell volumes
were 1700 Im3. Assuming that this median cell volume
represents tumour cells, and using an inverse tumour density
of 1 cm3 g-1, which experiments correlating tumour volume
to weight in clone A tumours indicate is a statistically valid
assumption (Leith and Michelson, 1994), we estimate that
average size and 95% confidence limits of the parenchymal
compartment (P) is 9.5% (± 7.8%) of the total tumour, with
the remaining 90.5% therefore being non-tumour tissues (NP
compartment). We calculate the fractional volume (FV) of
the P compartment as follows:
(5.58 x I0 tumour cells per mg of tumour)
(1.7 x 103IUm3 per tumour cell)
9.49 x 107fLm3 of tumour cells mg-'
and with 109 fLm3 mg tumour, the FV (mg of tumour cells
per mg of tumour) = 0.095. With regard to the potential
significance of this calculation of the fractional volume of
tumour tissue occupied by tumour cells per se, it is infor-
mative to examine the correlation between FGF-2 levels in
cells (pg IO6 cells) and levels in whole tumours (pgmg-'
tumour). The least-squares linear regression equation of the
best fit to the respective (log) data pairs from the same
tumours was log FGF-2 (pgmg-' tumour) =0.002+ 0.681
log FGF-2 (pg 10-6 cells). The correlation coefficient of 0.827
is statistically significant (t= 3.89, P<0.05; Goldstein, 1964),
and indicates that FGF-2 levels in P and (P + NP) compart-
ments are strongly correlated, as would be expected. We also
note that if the increase in FGF-2 levels in whole tumours
was a reflection of increases in levels in parenchymal tumour
cells only (that is if levels in NP were constant), the slope of
this curve im such a situation would be predicted to be about
0.22. The 95% confidence limits on the slope of the response
are ± 0.413. This value is less than that for the lower limit on
the slope given by the 95% confidence limits cited above (i.e.
0.27), which suggests an additional FGF-2 source. Related to
this, absolute levels of FGF-2 vary widely from tumour to
tumour. Why there should be such inter-tumour variation in
steady-state levels of FGF-2 for neoplasms of the same
average size requires discussion. Neither the levels of FGF-2
in parenchymal tumour cells nor the levels in whole tumour
extracts showed a significant correlation with tumour volume
over the limited range of volumes studied herein (respective
correlation coefficients were -0.22 and - 0.12). However, as
noted above, there is a large variation in the fractional
volume of the tumour occupied by parenchymal cells (95%
confidence limits approximately 1.8-17.3%). Additionally,
because at this average tumour size, of the order of
27% ±7% (95% confidence limits) of the P compartment
may be macrophages (Leith and Michelson, 1994), this
indicates that the relative percentage of macrophages in any
given neoplasm could vary in the extreme from possibly as
low as 0.4% to as high as 6% of total cells in the P
compartment, i.e. a difference of about 15-fold. On this
point, the range of FGF-2 values expressed among different
tumours as either pg 10-6 cells or pgmg-1 tumour was
roughly of the same order of magnitude. These data imply
that the high levels of FGF-2 seen in vivo as well as the
variability from tumour to tumour could be the result of host
cells. We note also that. although there was no dependence
of FGF-2 levels on tumour volume, there was a strong
inverse correlation of (log) FGF-2 levels (pg 10-6 cells) in the
disaggregate to the (log) of the absolute cellularity of the
disaggregate as defined by the cell yield. The best fit linear
regression equation was: log FGF-2 (pg 10-6cells)
= 3.832 -
0.2378 log cellsmg-' ( x 104). The correlation coefficient
was - .844 (t = 3.85, P<0.05; Goldstein, 1964). The inter-
pretation of this inverse relationship may relate either to
different levels of larger vs smaller cells in the disaggregate
(e.g. macrophages, large and small tumour cells) and/or to
different steady-state levels ofhypoxia in different tumours, a
factor which has been associated with a larger fraction of
smaller cells in solid tumours (Pallavicini et al., 1979).
Related to this issue of the inverse correlation between
tumour cellularity and FGF-2 levels per cell seen in vivo is
the fact that macrophages contain FGF-2 (Frautschy et al.,
1991; Motoo et al., 1991; Logan et al., 1992; Greisler et al.,
1993; Hughes et al., 1993). Indeed, Baird et al. (1985)
indicated that FGF-2 levels in activated peritoneal macro-
phages were approximately S ng 10-6 cells, a level high
enough to be consistent with a macrophage-endothelial cell
mitogenic paracrine loop. In this regard, a review of the
literature indicates that typical macrophage percentages in
cell suspensions from disaggregated sarcomas and carcinomas
(geometric means and 95% confidence limits) are respectively
about 30% (19-48%) and 34% (20-57%) (Evans, 1977;
Siemann et al., 1981; Milas et al., 1987; West et al., 1987).
Therefore, the high levels of FGF-2 found in clone A
tumours may be coming from the intermixed host cells.
Indeed, calculation of a rough weighted average of FGF-2
concentrations as measured in the disaggregate assuming
90% parenchymal tumour cells and 10% macrophages using
the FGF-2 values for unfed plateau phase clone A cells
(Table I) and the macrophage results from Baird et al. (1985)
indicates that the presence of a significant fraction of mac-
rophages in the disaggregate could easily lead to the values
listed in Table I of approximately 100 pg 10-6 cells. We note
that the typical volume of macrophages (: 1500jim3; Haupt-
mann et al., 1993) is very similar to the mean volume
obtained in Coulter counter size distribution data from disag-
gregated clone A tumours (1700;Lm3). Centrifugal elutriation
studies on exponentially growing clone A cells show that the
fraction of cells with this average volume would consist of
approximately 72%, 25% and 3% of cells in GI, S and
G2 + M respectively (Bliven et al., 1987). Instantaneous
determinations of S-phase [3H]thymidine labelling indices in
clone A tumours of the size examined in these studies are in
good agreement with the flow cytometry data obtained from
centrifugal elutnation upon unfed plateau cultures (Bliven et
al., 1987; Leith and Michelson, 1994). These proportions are
therefore probably reasonable representations of conditions
in vivo. The similarities in average cell volumes between
unfed plateau clone A cells in vitro, macrophages and cellular
disaggregates of solid clone A tumours illustrate a problem
with simple descriptions of total cell yields after
haemocytometer estimation, and indicate that additional care
must be taken with regard to adequate definition of tumour
composition for proper interpretation of growth factor condi-
tions in solid neoplasms.
Average FGF-2 levels in clone A neoplasms are approx-
imately 24 pg of FGF-2 per mg of tumour (24 ng ml -,
assuming unit density) (Table I). This calculation neglects
any correction for the necrotic component of clone A neop-
lasms, which is approximately 10% at a volume of 750 mm3
Leith and Michelson, 1994). Using a vital dye staining
method for differentiating between viable and necrotic
regions of solid tumours described by Porschen et al. (1983),
we have determined that low levels (about 20% of levels in
viable tissue on a per mg basis) of FGF-2 exist in necrotic
tissue (JT Leith, unpublished data, 1994). While this value
may represent contamination of necrotic tissue by viable
tissue carried over during tumour micro-dissection, other
growth factor assays indicate that levels of platelet-derived
growth factor are identical in viable and necrotic tissue
(about 16 pg mg-'; JT Leith, unpublished data, 1994).
It may be necessary to investigate whether significant levels
of other growth factors are also present in necrotic regions.
To our knowledge, little attention has been given to the
partitioning of growth factors between viable and necrotic
portions of neoplasms. In justification, we note that the
necrotic portion of solid tumours has been postulated as a
site for production of growth-inhibitory proteins (Freyer, 1988).
With regard to autocrine and paracrine effects in clone A
neoplasms, levels of FGF-2 in vitro (i.e. 2 -8 pg 10 6cells, Table I) are orders of magnitude lower than levels reported for human or bovine endothelial cells in vitro (2-13 ng 106
cells) (Hannan et al., 1988). The in vitro results therefore
suggest that FGF-2 released from clone A tumour cells viaFG2 hm .. colon tumour cel
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processes such as mitogenic or apoptotic cell death would not
constitute an effective paracnrne loop between tumour cells
and capillary endothelium in vivo. In contrast, FGF-2 bin-
ding studies on clone A cells show that they possess high-
affinity binding sites for FGF-2 (KD approximately 49 ± 20
pM). Moscatelli et al. (1986) found KD values ranging from
7.3 to 47.0 pM in six different mammalian cell lines, and
Gross et al. (1993) found a value of 46 pM for C6 rat glioma
cells. Also, clone A cells respond mitogenically to exogenous
FGF-2 (ED50 4.8 pM) suggesting that an autocrine loop may
exist in vivo. A similar ED50 has been determined for C6 rat
glioma cells by Gross et al. (1993). The number of binding
sites per cell calculated from B, and the specific activity at
saturation using a molecular weight of FGF-2 of 17 200 Da
was 3.95 x 10i. The number of FGF-2 binding sites reported
for other cell lines range from about 103 to as high as 6 x 104
(Moscatelli et al., 1986; Murono et al., 1992; Gross et al.,
1993). It should be noted that clone A cells are exceptionally
large cells with average volumes in exponential growth of
approximately 2200 iLM3 (Bliven et al., 1987). This would
correspond to a surface area of about 820p,m2, yielding a
binding site density of about 21 sitespm-2. In vivo, overall
FGF-2 levels in clone A neoplasms are high, approximately
28 pg mg-' tumour (29 ngml-', assuming unit density). With
regard to the potential physiological significance of these
FGF-2 levels, D'Amore and Smith (1993) have shown that
proliferation of bovine aortic or capillary endothelial cells
was maximally stimulated by FGF-2 levels of about
2.5-4ngml', and that half-maximal stimulation occurred
at levels of about 0.6-1 ng mal'. There therefore appears to
be, as viewed on the gross level, an adequate concentration
of FGF-2 in clone A tumour tissue to satisfy requirements
for neoangiogenesis (D'Amore & Smith, 1993; Schwartz,
1993). This finding is consistent with the low steady-state
levels of intratumour hypoxia observed in clone A neoplasms
(Leith et al., 1991a).
In summary, although these results still support the
hypothesis that levels of angiogenic growth factors such as
FGF-2 in vivo may be related to hypoxia, the complex
biological processes involved in these results require further
study. As noted above, because these factors may be derived
from host cells rather than parenchymal tumour cells, the
variability in steady-state levels of intra-tumour hypoxia
among various tumour models could result from host cell-
related paracrine effects. This speculation is supported by the
fact that levels of FGF-2 in clone A cells appear insufficient
to create an effective paracrine loop. However, long-term
binding of FGF-2 to HSPGs could provide a functional link
between apparently low instantaneous cellular levels and high
steady-state tumour levels. Separation of host from tumour
cells by centrifugal elutriation (West et al., 1987) with ELISA
analysis of subpopulation growth factor levels to address
these possibilities is therefore an important future goal. Addi-
tionally, there are numerous dynamic interconnections
among growth factors/cytokines etc. (Michelson and Leith,
1993, 1994) whose functional significance in vivo is poorly
determined at present. Because potent synergistic interactions
have been shown to occur between growth factors such as
FGF-2 and VEGF (Pepper et al., 1992; Goto et al., 1993),
the levels of other stimulatory angiogenic factors (e.g.
VEGF) need to be defined to determine which growth fac-
tor(s) is(are) of importance in determination of steady-state
levels ofintraneoplastic hypoxia. Lastly, these results indicate
that in vitro studies alone may be inadvertently misleading
with regard to the accuracy of models of solid tumour
physiology, illustrating the necessity of appropriate in vivo
measurements (Soutter et al., 1993).
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